TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03249792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (SC)
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (SC)
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (SC)
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (SC)
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (SC)
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (SC)
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (SC)
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (SC)
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (SC)
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (SC)
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT01025791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study: NCT03249792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT01025791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study: NCT03249792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT00469144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Fixed Dose = 130 mg/m\^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m\^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Fixed Dose = 130 mg/m\^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m\^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 IV Daily Over 1 Hour x 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 IV Daily Over 1 Hour x 4 Days
Study: NCT04051034

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Active: 1.25 g capsules/420 35-count bottles \[1.25 g capsule contains min. 750 mg EPA + 250 mg DHA\] and heat therapy, increase internal body temperature 1.2 C above baseline.~Placebo: 14,700 1.25 g capsules/420 35-count bottles \[1.25-gram high oleic safflower oil capsule\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active: 1.25 g capsules \[1.25-gram high oleic safflower oil capsule\] and heat therapy, increase internal body temperature 1.2 C above baseline.
Study: NCT00869336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Cream 1% - 2 wks
Description: Topical cream applied daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator -2 wks
Description: Placebo cream applied daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Cream 1% - 4 wks
Description: Topical cream applied daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator - 4 wks
Description: Placebo cream applied daily for 4 weeks
Study: NCT03471000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short implants Treatment
Description: Short implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular implants Treatment
Description: Sinus lift procedure is done and regular implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
Study: NCT03764098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine ER
Description: Guanfacine Extended Release (6mg/day ER)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03477903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 0.9% sodium chloride for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 0.9% sodium chloride for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 0.9% sodium chloride for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride for injection
Study: NCT03582748

Intervention type: PROCEDURE
Intervention: sleeve gastrectomy
Description: removal of most of stomach as a bariatric surgical procedure

Intervention type: PROCEDURE
Intervention: sleeve gastrectomy
Description: removal of most of stomach as a bariatric surgical procedure

Intervention type: PROCEDURE
Intervention: No sleeve gastrectomy
Description: Non-receipt of sleeve gastrectomy procedure
Study: NCT03597529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: melatonin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: melatonin
Study: NCT02481362

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAKE
Description: For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAKE
Description: For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APRICOTS
Description: For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APRICOTS
Description: For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
Study: NCT03263897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insufflation
Description: mobile interface driven insufflation of the ear canal

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: insufflation
Description: mobile interface driven insufflation of the ear canal

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo insufflation
Description: mobile interface driven placebo insufflation of the ear canal
Study: NCT00952731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo
Description: Oral placebo taken daily for 4-10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afimoxifene
Description: 2mg/breast applied daily in the form of a gel for 4-10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo gel
Description: Placebo gel applied to breasts daily for 4-10 weeks.
Study: NCT02055664

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 0.2%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorure de sodium 0.9%
Study: NCT00704847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Salmon Calcitonin
Description: 0.8mg SMC021, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Salmon Calcitonin (Placebo)
Description: 0.8mg Placebo, twice daily
Study: NCT01811316

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Study: NCT04223557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: focused power ultrasound treatment
Description: Patients will be placed in the lateral decubitus position and receive treatment with sequential bilateral PRF ablation. Before the treatment, a professional sonographer will be responsible for the length, thickness, and width of PRF sac measurement and localisation, and utilise the ultrasonic diagnostic transducer to delineate the targeted region. The treatment will launch layer-by-layer. After confirming accurate localization of the treatment, layer-by-layer PRF ablation will be performed on the patients. The device generates and delivers a pattern of conic-shaped ultrasound energy to the PRF sac noninvasively. The treatment of FPU-mediated PRF ablation will be implemented once.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Participants will receive the same procedure as those in the FPU treatment including PRF ultrasonic measurement and localization and focused ultrasound treatment parameters setting, except that no energy will be delivered to the PRF.
Study: NCT00303459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching bosentan placebo/b.i.d.
Study: NCT01025791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study: NCT01440933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: 1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
Study: NCT02203500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study: NCT04347733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 40mg/mL
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 40mg/mL
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40mg/mL
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronidase Injection
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
Study: NCT03001440

Intervention type: OTHER
Intervention: KAB survey
Description: The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
Study: NCT01292863

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Conventional peritoneal dialysis solution
Description: Daily dialysis solution to be used for 3 months in crossover fashion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Novel biocompatible dialysis solution
Description: Daily dialysis solution to be used for 3 months in crossover fashion.
Study: NCT02432300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Builder
Description: Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
Study: NCT04553549

Intervention type: DEVICE
Intervention: Transradial approach
Description: Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr).
Study: NCT04495426

Intervention type: OTHER
Intervention: Non-interventional study
Description: There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.

Intervention type: OTHER
Intervention: Non-interventional study
Description: There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.
Study: NCT03481777

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning
Description: RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning
Description: Sham Comparator (Sham-RIC)
Study: NCT04286451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Women will be undergo 4 nights of sleep restriction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habitual Sleep
Description: Women will be undergo 4 nights of habitual sleep.
Study: NCT04495426

Intervention type: OTHER
Intervention: Non-interventional study
Description: There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.
Study: NCT05945719

Intervention type: BEHAVIORAL
Intervention: Behavioral therapy
Description: Behavioral and supportive therapy
Study: NCT03180216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virus Specific T cells (VSTs)
Description: This Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors.~In this trial, we will utilize a rapid generation protocol for broad spectrum multivirus-specific T cells for infusion to recipients of allogeneic hematopoietic stem cell transplant (HSCT), who are at risk of developing EBV, CMV, adenovirus, HHV6, BKV, JCV and/or HPIV3, or with PCR/culture confirmed active infection(s) of EBV, CMV, adenovirus, HHV6, BKV, JCV, and/or HPIV3 that has failed to resolve with at least 14 days of standard antiviral therapy (if available and tolerated). These cells will be derived from HSCT donors, and the study agent will be assessed at each dose for evidence of dose-limiting toxicities (DLT).
Study: NCT03991897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketocal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals will be used. After 24 weeks a Modified Atkins diet will be started.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric diet
Description: Patients will follow an isocaloric diet